ITF 3756

• Description:

  ITF 3756 is a potent and selective HDAC6 inhibitor. ITF 3756 reduces in vitro the expression of PD-L1 on human monocytes and on CD8 T cells, and shows anti-tumor activity[1].

• UNSPSC:

  12352005

• Target:

  HDAC

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage; Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/itf-3756.html

• Purity:

  98.55

• Solubility:

  DMSO : 125 mg/mL (ultrasonic)

• Smiles:

  O=C(C1=CC=C(CN2N=NN=C2C3=CC=CS3)C=C1)NO

• Molecular Formula:

  C13H11N5O2S

• Molecular Weight:

  301.32

• References & Citations:

  [1]Gianluca Fossati, et al. Abstract 1358: The selective HDAC6 inhibitor ITF3756 stimulates an antitumor immune response and leads to tumor regression in combination with anti CTLA-4 antibody in a colon carcinoma murine model. Cancer Res (2022) 82 (12_Supplement) : 1358.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  2247608-27-9